Intellia Therapeutics, Inc.
Prognozy (mln)
| Okres |
2024-12-31 |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
53.93 |
55.25 |
45.24 |
316.91 |
1,082.38 |
2,284.27 |
| Przychód Δ r/r |
0.00% |
2.45% |
-18.11% |
600.42% |
241.55% |
111.04% |
| Przychód (min) |
45.78 |
7.08 |
44.34 |
315.53 |
219.87 |
464.01 |
| Przychód (max) |
63.58 |
165.23 |
46.15 |
318.28 |
3,603.40 |
7,604.69 |
| EBITDA (średnia) |
-53.93 |
-55.25 |
-45.24 |
-316.91 |
-1,082.38 |
-2,284.27 |
| EBIT (średnia) |
-53.93 |
-55.25 |
-45.24 |
-316.91 |
-1,082.38 |
-2,284.27 |
| EBIT % |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
-100.00% |
| Zysk netto (średni) |
-525.91 |
-412.38 |
-442.09 |
-175.78 |
275.00 |
1,043.27 |
| Zysk netto % |
-975.19% |
-746.41% |
-977.10% |
-55.47% |
25.41% |
45.67% |
| EPS (średnia) |
-5.31 |
-4.17 |
-3.87 |
-1.75 |
2.78 |
10.55 |
| Liczba analityków (Przychody) |
21 |
18 |
25 |
17 |
9 |
14 |
| Liczba analityków (EPS) |
18 |
20 |
23 |
13 |
9 |
11 |
| symbol |
NTLA |
NTLA |
NTLA |
NTLA |
NTLA |
NTLA |